STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent.

Slides:

Advertisements

Similar presentations

Uptake of T-MPs for DC maturation and antigen presentation.

Advertisements

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

The absence of ADCC by nivolumab in vitro.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced cells. A role for galectin-3 in promoting lung colonization in ST6GalNAc2-silenced.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

ILK knockdown increases the survival of PKD mice.

IL-27 contributes to IR expression by lung T cells during toxoplasmosis. IL-27 contributes to IR expression by lung T cells during toxoplasmosis. (A) Il27p28-GFP.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

CD160 on CD8+ T cells is required for optimal clearance of L

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

SYK activity is required for anti-IgM–induced CD86 expression.

Expression of p110γ isoform in macrophages promotes tumor growth and angiogenesis. Expression of p110γ isoform in macrophages promotes tumor growth and.

Exosome-mediated inhibition of T cells is reversible.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Reduced tumor growth in CCR5-deficient mice is associated with perturbed killing ability of Treg cells. Reduced tumor growth in CCR5-deficient mice is.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Stereotactic radiotherapy increases Tregs in tumors.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

Cytokine expression in the ileum and colon.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

CD25 expression predicts effector and memory differentiation.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

CD4+ and CD8+ TILs express surface CD137.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation by Kate A. Markey, Tatjana.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

A protracted ketogenic diet increases radiation response in H292 lung cancer xenografts given conventional fractionated radiation. A protracted ketogenic.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing BALB/c mice following VP-16 pretreatment. Micro-PET/CT images of 64Cu-Sar-chTNT-3 in MAD109-bearing.

Neutralization of CSF1 and Ad5-HRG treatment.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

Crebbp deficiency accelerates B-cell lymphoma development in mice.

HMQ1611 inhibited breast tumor growth in mice.

Mean cell number in small intestinal crypt (a), small intestinal villus (b), and midcolonic crypt (c) of BALB/c (♦) and DBA/2 (▪) mice after two injections.

Apoptotic cell index percentage (a and b) and mitotic cell index percentage (c and d) in small intestinal (a and c) and midcolonic (b and d) crypts of.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

C7R enhances adoptive T-cell immunotherapy against metastatic and intracranial malignancies.A and B, 1 × 106 CHLA-255 FFluc cells were injected i.v. into.

Mean weight change from original weight of (a) BALB/c (b) DBA/2 mice after one (♦) or two (▴) injections of 10 mg/kg and one (▪) or two (×) injections.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Immunotherapy of NK-92-S3KD increases anticancer effector productions in HepG2-bearing mice. Immunotherapy of NK-92-S3KD increases anticancer effector.

Role of NO and IFNγ in mast cell–dependent MDSC-suppressive activities

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

The CCR5+ population of SUM-159 cells is enriched with tumor-initiating cells. The CCR5+ population of SUM-159 cells is enriched with tumor-initiating.

Comparative effect of anti-TIM3 against experimental tumors.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Presentation transcript:

STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. A, Experimental plan to assess the effect of DMXAA on mAb immunotherapy. B and C, FcγR expression (B) and A:I ratio (C) on splenic macrophages on day 21 after BCL1 inoculation (error bar ± SEM). D–F, Kaplan–Meier survival curve for WT BALB/c mice (D), FcγR-null BALB/c (E), or WT BALB/c (F) in the presence or absence of CD8+ T-cell–depleting antibody (n = 8–10, Mantel–Cox test). Lekh N. Dahal et al. Cancer Res 2017;77:3619-3631 ©2017 by American Association for Cancer Research